.Nature Medicine, Released online: 09 Oct 2024 doi:10.1038/ s41591-024-03316-9Delandistrogene moxeparvovec obtained FDA authorization after a damaging test, which highlights the numerous complications and challenges of medication advancement in this particular setting.